Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.83 |
| ▸ | MMP1 | P03956 | 16/20 | 0.83 |
| ▸ | PGR | P06401 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11812693 | 1.00 | NR3C1 (0.83) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL7547 | 1.00 | NR3C1 (0.83) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL147590 | 0.99 | NR3C1 (0.82) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL1265487 | 0.99 | NR3C1 (0.82) | NR3C1MMP1PGRCYP3A4MEN1 | |
| Dexamethasone SCHEMBL3681477 | 0.95 | NR3C1 (0.84) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL16094588 | 0.93 | NR3C1 (0.81) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL11582615 | 0.93 | NR3C1 (0.74) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL11583661 | 0.93 | NR3C1 (0.75) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL11582612 | 0.93 | NR3C1 (0.74) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL11582295 | 0.93 | NR3C1 (0.74) | NR3C1MMP1PGRCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| EP-0259983-A2 | The use of corticosteroids for amelioration or elimination of postoperative pain | Cary Jr., George R. (US) | 1988-03-16 | — | — | EP | claimed |
| US-20160272635-A1 | SUBSTITUTED DIHYDROPYRIDO[3,4-B]PYRAZINONES AS DUAL INHIBITORS OF BET PROTEINS AND POLO-LIKE KINASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160009725-A1 | PYRROLO- AND PYRAZOLO-TRIAZOLODIAZEPINES AS BET-PROTEIN INHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20150376196-A1 | 4-SUBSTITUTED PYRROLO- AND PYRAZOLO-DIAZEPINES | Bayer Pharma AG (DE) | 2015-12-31 | — | — | US | disclosed |
| US-9212140-B2 | (5s,8s)-3-(4′-chlor-3′-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatment | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-20150344444-A1 | BET-PROTEIN-INHIBITING DIHYDROXYQUINOXALINONES | Bayer Pharma AG (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20140031407-A1 | (5S,8S)-3-(4'-CHLOR-3'-FLUOR-4-METHLYBIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE (COMPOUND A) FOR TREATMENT | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20130210846-A1 | USE OF NOVEL PAN-CDK INHIBITORS FOR TREATING TUMORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-0259983-B1 | The use of corticosteroids for amelioration or elimination of postoperative pain | CARY GEORGE R JR (US) | 1995-02-15 | — | — | EP | disclosed |
| US-5272139-A | Amelioration or elimination of postoperative pain | CARY GEORGE R JR (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0259983-A2 | The use of corticosteroids for amelioration or elimination of postoperative pain | Cary Jr., George R. (US) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | NR3C1 152/4885MMP1 4826/4885PGR 305/4885 |
| US-20150344444-A1 | BET-PROTEIN-INHIBITING DIHYDROXYQUINOXALINONES | BRD4, BET1, BRDT | NR3C1 2024/4885MMP1 3530/4885PGR 1579/4885 |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BRD4, BET1, BRDT | NR3C1 1464/4885MMP1 3495/4885PGR 1078/4885 |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BRD4, BRDT, BET1 | NR3C1 2118/4885MMP1 3587/4885PGR 1352/4885 |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BRD4, BRDT, BICRA | NR3C1 136/4885MMP1 4560/4885PGR 965/4885 |
| US-20160272635-A1 | SUBSTITUTED DIHYDROPYRIDO[3,4-B]PYRAZINONES AS DUAL INHIBITORS OF BET PROTEINS AND POLO-LIKE KINASES | PLK3, PLK2, PLK4 | NR3C1 2092/4885MMP1 3114/4885PGR 666/4885 |
| US-20160009725-A1 | PYRROLO- AND PYRAZOLO-TRIAZOLODIAZEPINES AS BET-PROTEIN INHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | BRDT, BRD3, BRD1 | NR3C1 652/4885MMP1 4468/4885PGR 1003/4885 |
| US-20140031407-A1 | (5S,8S)-3-(4'-CHLOR-3'-FLUOR-4-METHLYBIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE (COMPOUND A) FOR TREATMENT | AZI2, CYP8B1, VHL | NR3C1 64/4885MMP1 3366/4885PGR 1971/4885 |
| US-20130210846-A1 | USE OF NOVEL PAN-CDK INHIBITORS FOR TREATING TUMORS | CDK3, CDKL1, CDK4 | NR3C1 2176/4885MMP1 4123/4885PGR 1063/4885 |
| US-20150376196-A1 | 4-SUBSTITUTED PYRROLO- AND PYRAZOLO-DIAZEPINES | BRDT, BRD4, BRD3 | NR3C1 260/4885MMP1 4512/4885PGR 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.